Treatment of Systemic Rash
Introduction
- Systemic rash treatment guidelines are supported by the British Association of Dermatologists and the British Journal of Dermatology, with recommendations for disease management and treatment approaches 1, 2
Dosage and Administration
- For moderate to severe systemic rash, prednisone should be dosed at 0.5-1 mg/kg/day, with mild or localized disease receiving 0.5 mg/kg/day and severe widespread disease receiving 0.75-1 mg/kg/day, as recommended by the British Association of Dermatologists 1
- The British Association of Dermatologists recommends tailoring the dose to disease severity for bullous pemphigoid, with doses of 0.75-1 mg/kg/day for severe involvement, 0.5 mg/kg/day for mild or localized disease, and 0.3 mg/kg/day for moderate disease 1
- For grade 3 dermatologic toxicity from immune checkpoint inhibitors, prednisone 0.5-1 mg/kg/day is recommended until symptoms resolve to grade 1 or less 3
- Clobetasol propionate 0.05% cream applied to lesions only, twice daily, is recommended as the first-line treatment for bullous pemphigoid, due to its effectiveness and fewer systemic side effects compared to oral corticosteroids 2
- Dapsone should be considered as a second-line or adjunctive treatment for bullous pemphigoid when first-line treatments are ineffective, contraindicated, or causing significant side effects, with a starting dose of 50 mg/day and a therapeutic range of 50-200 mg/day (typically 1.0-1.5 mg/kg/day) 2, 1
- Azathioprine (1-2.5 mg/kg/day) and tetracycline (e.g., doxycycline 200-300mg daily) with nicotinamide are recommended as steroid-sparing agents 2
- Other steroid-sparing agents, such as mycophenolate mofetil (0.5-1g twice daily), methotrexate (5-15 mg weekly), dapsone (50-200 mg daily), and chlorambucil (0.05-0.1 mg/kg/day), can be considered for disease not responding to initial treatment or relapsing on high doses 4, 1
Treatment Duration and Tapering
- Total treatment duration typically ranges from 4-12 months 5
- Initial treatment should be maintained until disease control is achieved, typically within 1-4 weeks, then tapering can begin 1
- The tapering regimen involves reducing the dose by one-third or one-quarter down to 15 mg daily at fortnightly intervals, then by 2.5 mg decrements down to 10 mg daily, and finally by 1 mg each month 1
- The goal is to aim for a minimal therapy dose of 0.1 mg/kg/day within 4-6 months 5
- Disease control should be achieved within 1-4 weeks, as defined by the absence of new inflammatory or blistered lesions, and assessment for disease control should be done after 2-3 weeks of treatment 5, 1
- The British Journal of Dermatology defines control as the absence of new inflammatory or blistered lesions, which can be assessed after 3 weeks of treatment, and recommends using a BPDAI score threshold of 49 points to help predict disease control at day 21 1
Wound Care and Supportive Measures
- Elevation of the legs, use of compression stockings (if no open lesions), gentle exercise, avoidance of prolonged standing or sitting, leaving small to medium-sized blisters intact, and draining larger blisters are recommended for wound care, as suggested by the British Journal of Dermatology guidelines 1, 5
- Application of non-adherent dressings to erosive lesions and antisepsis baths are also recommended, as well as the use of proton pump inhibitors for gastric protection, calcium and vitamin D supplements, and consideration of bisphosphonates to prevent osteoporosis, according to the British Journal of Dermatology guidelines 1
- Avoidance of furosemide is recommended due to its association with bullous pemphigoid as an adverse reaction, as noted by the British Journal of Dermatology guidelines 1, 5
Monitoring and Follow-up
- Weekly blood counts are recommended initially, then monthly once stable, with monitoring for hemolysis, methemoglobinemia, and agranulocytosis, liver function tests every 3 months, and assessment of clinical response after 2-3 weeks, as advised by the British Journal of Dermatology guidelines 2
- In elderly patients, close monitoring is essential due to increased risk of adverse effects, as recommended by the British Journal of Dermatology guidelines 2
- Consider anti-BP180 IgG ELISA at days 0, 60, and 150 to predict outcome, as recommended by the British Journal of Dermatology 5
- Implement osteoporosis prevention from the start of therapy, including vitamin D and calcium supplements, and consider bisphosphonates for treatment >3 months, although specific guidelines may vary 5, 2
- Vaccinate against influenza and pneumococci (avoid live vaccines), as recommended by the British Journal of Dermatology 5
Relapse and Discontinuation
- If relapse occurs during tapering, return to the previous effective dose, and if relapse occurs after treatment discontinuation, restart at the appropriate dose based on severity, as recommended by the British Journal of Dermatology 5
- Relapse is defined as new blisters, eczematous lesions, or urticarial plaques that don't heal within 1 week, and requires prompt reassessment and adjustment of treatment 5
- Treatment can be discontinued in patients who are symptom-free for at least 1-6 months on minimal therapy, although ongoing monitoring is necessary to detect potential relapse 5